GHRP-2 has human pharmacology data, but the best-known experiments were small and measured short-term appetite or growth-hormone responses. They do not establish body-composition, anti-aging or performance benefits.
Evidence at a glance
- A crossover study infused seven lean healthy men and found 35.9 ± 10.9% greater buffet-meal intake with GHRP-2 than saline.
- A five-day study in nine healthy men found attenuation of the GH response and no stimulation of circulating IGF-I.
- FDA lists safety concerns for compounded GHRP-2, while WADA prohibits GHRP-2 in sport.
Study record
In the seven-person study, participants received a 270-minute subcutaneous infusion at 1 µg/kg/hour or saline before an unrestricted buffet. Every participant ate more under GHRP-2. The result supports an acute orexigenic effect in that protocol; it is not evidence for weight loss or a recommended regimen.
Results in context
The five-day study measured repeated GH responses and IGF-I in nine men. Response attenuation and the absence of IGF-I stimulation are important because they prevent a simple “more GH means durable anabolic effect” narrative.
FDA states that compounded GHRP-2 may pose immunogenicity risks and notes serious adverse-event reports for which causality has not been established. WADA includes pralmorelin/GHRP-2 among prohibited GH-releasing peptides.
What the evidence cannot establish
Seven and nine participants are insufficient for broad safety or efficacy conclusions.
Hormone AUC and food intake are surrogate or short-term endpoints.
The cited interventions do not validate the identity, sterility or safety of a catalog lot.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
5 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- GHRP-2 and food intake in healthy menSeven-person human crossover physiology study; PMID 15699539.
- Five-day GHRP-2 treatment in healthy menNine-person repeated-response study; PMID 9820615.
- PubChem Pralmorelin recordSequence, stereochemistry, formula and molecular weight; CID 6918245.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
- WADA 2026 Prohibited ListOfficial list prohibits mechano growth factors.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
